The 2017 Access to Vaccines Index has mapped how vaccine companies are responding to global calls to improve immunisation coverage. The companies approach access to vaccines in differing ways, which are generally linked to their diverse pipelines, portfolios, revenues and sales.

The Index has identified three key findings: related to R&D for vaccine adaptations, vaccine pricing, and aligning supply and demand.

Adaptations to existing vaccines account for half of vaccine R&D projects

The Access to Vaccines Index has evaluated the pipelines of eight vaccine companies: Daiichi Sankyo, GSK, Johnson & Johnson, Merck & Co., Inc., Pfizer, Sanofi, Serum Institute of India and Takeda. The industry is responding to cases where existing vaccines need to be adapted: such projects account for 48% of projects in the pipeline (43/89), with one project aiming for multiple adaptations.
Continue reading

When setting prices, all companies consider countries’ Gavi status

The Access to Vaccines Index asked six companies which factors they consider when setting vaccine prices: GSK, Johnson & Johnson, Merck & Co., Inc., Pfizer, Sanofi and Serum Institute of India. Collectively, the six companies consider 18 diverse factors when setting vaccine prices, with the most attention being paid to the conditions (not least economic conditions) in a given country. Indeed, the only factor considered by all six companies is a country’s eligibility for Gavi support.
Continue reading

Companies take diverse approaches to aligning supply with demand

The Access to Vaccines Index has evaluated the approaches taken by six companies in aligning vaccine supply with global demand: GSK, Johnson & Johnson, Merck & Co., Inc., Pfizer, Sanofi and Serum Institute of India. All six companies implement a combination of the elements assessed. No particular combination is identified as best practice, but implementing more elements is expected to better prevent shortages. Each company's approach is likely to be linked to its portfolio, structure and business model.
Continue reading

Sign up to receive updates about our work.